IGFBP2 and urinary bladder carcinoma: Having shown that IGFBP-2 was re-expressed in T24 and TCCSUP cells following AZA treatment, COBRA was then performed with these two cell lines to assess any alterations in gene methylation status of the IGFBP-2 promoter and to confirm whether the loss of IGFBP-2 in mesenchymal-like bladder cancer cell lines could be the result of an epigenetic change.